Panexo Biosciences AB - Treatments against metabolic syndrome and obesity

Panexo is a subsidiary of Exocure Sweden AB and is in a joint venture with a company in Singapore and develops a drug delivery technology, where vesicles are loaded with relevant molecules and can thus be administered orally instead of subcutaneously or intravenously. The first products are treatments against metabolic syndrome and obesity. By using a lower dose that is delivered via exosomes to the right target, new drugs can be developed.

Impact: This can lead to highly effective treatments with fewer side effects and can lead to better health for more people.

GUV Contact: Helena Lundquist